ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200-Day Moving Average – Here’s Why

ImmuCell Co. (NASDAQ:ICCC) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.40 and traded as high as $4.97. ImmuCell shares last traded at $4.97, with a volume of 2,110 shares traded.

ImmuCell Price Performance

The stock’s 50-day simple moving average is $5.17 and its two-hundred day simple moving average is $4.41. The firm has a market cap of $43.98 million, a P/E ratio of -9.87 and a beta of 0.62. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%. The company had revenue of $7.75 million for the quarter.

Institutional Investors Weigh In On ImmuCell

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mesirow Financial Investment Management Inc. increased its stake in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 12,178 shares during the period. Citadel Advisors LLC bought a new position in shares of ImmuCell in the fourth quarter worth about $149,000. Northern Trust Corp grew its holdings in shares of ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 14,982 shares during the last quarter. Geode Capital Management LLC increased its stake in ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after buying an additional 7,878 shares during the period. Finally, Dauntless Investment Group LLC bought a new stake in ImmuCell during the 4th quarter valued at about $676,000. 13.47% of the stock is owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.